INmune Bio Inc

NASDAQ INMB

Data sourced from

and

Download Data

INmune Bio Inc Sales to Working Capital Ratio 3 year CAGR for the quarter ending March 31, 2024: 136.92%

INmune Bio Inc Sales to Working Capital Ratio 3 year CAGR is 136.92% for the quarter ending March 31, 2024. The sales to working capital ratio measures the revenue generated by a company relative to its working capital. It is calculated by dividing the revenue by the difference between current assets and current liabilities. This ratio indicates the company's revenue generation efficiency based on its working capital. A higher sales to working capital ratio suggests better utilization of working capital to generate sales revenue. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

INmune Bio Inc Sales to Working Capital Ratio for the quarter ending March 31, 2023 was 0.00, a -63.06% change year over year.
INmune Bio Inc Sales to Working Capital Ratio for the quarter ending March 31, 2022 was 0.00, a 2,494.97% change year over year.
INmune Bio Inc Sales to Working Capital Ratio for the quarter ending March 31, 2021 was 0.00, a 0.00% change year over year.
INmune Bio Inc Sales to Working Capital Ratio for the quarter ending March 31, 2020 was 0.00, a 0.00% change year over year.

NASDAQ: INMB

INmune Bio Inc

CEO	Dr. Raymond Joseph Tesi M.D.
IPO Date	Feb. 4, 2019
Location	United States
Headquarters	980 North Federal Highway, Boca Raton, FL, United States, 33432
Employees	11
Sector	Healthcare
Industry	Biotechnology

Description

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Key trends